托珠单抗联合8周泼尼松治疗巨细胞动脉炎:单臂开放标签概念验证研究
这项前瞻性单臂概念验证研究在麻省总医院纳入30例新发或复发性活动性巨细胞动脉炎患者,给予12个月每周皮下注射托珠单抗162 mg联合8周泼尼松。第52周时23例(77%)达到持续无泼尼松缓解,7例(23%)复发,4例(13%)发生严重不良事件,研究期间无巨细胞动脉炎相关永久性视力丧失。
要点
- 30例患者全部在基线后4周内进入缓解,第52周77%达到持续无泼尼松缓解。
- 7例(23%)复发,平均复发时间15.8周(SD 14.7)。
- 4例(13%)发生严重不良事件,研究期间无巨细胞动脉炎相关永久性视力丧失。
核心结论
- 12个月托珠单抗联合8周泼尼松可能诱导并维持巨细胞动脉炎患者的缓解。
- 需要在随机对照试验中确认这些发现。
研究设计与样本
- 前瞻性、单臂、概念验证研究,在美国马萨诸塞州波士顿麻省总医院开展。
- 纳入30例年龄≥50岁、新发或复发性活动性巨细胞动脉炎患者,平均年龄73.7岁(SD 8.1),18例(60%)女性、12例(40%)男性,30例(100%)白人,15例(50%)新发疾病,23例(77%)颞动脉活检证实,14例(47%)影像学证实。
- 参与者接受12个月每周皮下注射托珠单抗162 mg联合8周泼尼松,主要终点为第52周持续无泼尼松缓解。
- 研究注册号ClinicalTrials.gov NCT03726749,已完成。
主要发现
- 2018年11月28日至2020年11月2日入组30例患者,初始泼尼松剂量为60 mg(n=7)、50 mg(n=1)、40 mg(n=7)、30 mg(n=6)、20 mg(n=9)。
- 全部患者均在基线后4周内进入缓解,第52周23例(77%)达到持续无泼尼松缓解。
- 7例(23%)复发,平均复发时间15.8周(SD 14.7)。
- 4例(13%)发生严重不良事件:1例仅与泼尼松相关或可能相关,2例仅与托珠单抗相关或可能相关,1例与泼尼松、托珠单抗或两者相关或可能相关。
- 2例无应答患者在第二次疾病复发后停用托珠单抗并提前退出研究,研究期间无巨细胞动脉炎相关永久性视力丧失病例。
临床怎么用
- 原文结论提示12个月托珠单抗联合8周泼尼松可能诱导并维持巨细胞动脉炎缓解,但作者指出需在随机对照试验中确认。
局限性
- 原文结论指出需在随机对照试验中确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Even after the approval of tocilizumab, substantial glucocorticoid exposure (usually ≥6 months) and toxicity continue to be important problems for patients with giant cell arteritis. We aimed to assess the outcomes of a group of patients with giant cell arteritis treated with tocilizumab in combination with 8 weeks of prednisone. METHODS: This prospective, single arm, proof-of-concept study was conducted at Massachusetts General Hospital (Boston, MA, USA). Individuals aged 50 years or older who had new-onset or relapsing giant cell arteritis with active disease were eligible for inclusion. Participants received 12 months of tocilizumab 162 mg weekly subcutaneously in combination with 8 weeks of prednisone. The primary endpoint was sustained prednisone-free remission at week 52. Adverse events were also evaluated. This trial is registered with ClinicalTrials.gov (NCT03726749), and is complete. FINDINGS: Between Nov 28, 2018, and Nov 2, 2020, we enrolled 30 patients (mean age 73·7 years [SD 8·1], 18 [60%] women and 12 [40%] men, 30 [100%] White race, 15 [50%] new-onset disease, 23 [77%] temporal artery biopsy-proven, 14 [47%] imaging-proven). The initial prednisone doses were 60 mg (n=7), 50 mg (n=1), 40 mg (n=7), 30 mg (n=6), and 20 mg (n=9). All patients entered remission within 4 weeks from baseline. 23 (77%) of 30 patients were in sustained prednisone-free remission at week 52 and seven (23%) patients relapsed, with a mean time to relapse of 15·8 weeks (SD 14·7). Overall, four (13%) participants developed a serious adverse event, including one related or probably related to prednisone exclusively, two related or probably related to tocilizumab exclusively, and one related or probably related to prednisone, tocilizumab, or both. Two of the non-responder patients stopped tocilizumab and withdrew from the study prematurely after having a second disease relapse. No cases of giant cell arteritis-related permanent vision loss occurred during the study. INTERPRETATION: These results suggest that 12 months of tocilizumab in combination with 8 weeks of prednisone could induce and maintain remission in patients with giant cell arteritis. Confirmation of these findings in a randomised controlled trial is required. FUNDING: Genentech.
引用
- Unizony S, Matza MA, Jarvie A, et al. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2023. PMID: 38251564. doi:10.1016/S2665-9913(23)00265-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。